EPE. A. Primakova

E. A. Primakova

*This is an algorithmically generated author record based on publicly available information.

E. A. Primakova has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intraportal induction of mesenchymal stem cells for immunosuppression induction in liver transplantation

    by S. V. Korotkov, E. A. Primakova, A. A. Symanovich, О. А. Лебедь, T. V. Lebedeva, A. E. Shcherba, S. I. Krivenko, O. O. Rummo

    Background. Despite the effectiveness of modern immunosuppressive therapy protocols, acute rejection remains a significant challenge in liver transplantation (LT), occurring in up to 40% of cases. One promising strategy to improve graft tolerance and reduce rejection rates is the use of mesenchymal stem cells (MSCs). Administering MSCs directly into the regional circulation of the transplanted liver offers the potential to enhance the effects of standard immunosuppressive therapy by exerting a localized immunosuppressive effect at the graft site. Objective: to evaluate the clinical efficacy of intraportal administration of MSCs during the induction phase of immunosuppressive therapy in patients undergoing LT. Materials and methods. A randomized prospective study was conducted involving two groups of LT recipients. In the experimental group (n = 14), patients received an intraportal infusion of MSCs during transplantation at a dose of 20 × 106 cells. The control group (n = 14) underwent standard transplant reperfusion without MSC administration. The study assessed the safety of the MSC infusion procedure, graft function, incidence and severity of acute rejection, renal function, and tacrolimus levels. Additional assessments included histological and immunohistochemical analyses, as well as fluorescence in situ hybridization (FISH). Results. No complications associated with MSC administration were observed. The MSC group demonstrated faster restoration of graft function, with significantly lower levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) by postoperative day 4 (p < 0.05), and normalization of AST achieved by day 10. The incidence of acute rejection was lower in the MSC group (21%) compared to the control group (28%), with only mild to moderate rejection observed in the MSC group. Additionally, expression of matrix metalloproteinase-10 (MMP10) was significantly reduced in the MSC group (p = 0.01). Tacrolimus levels were lower in the MSC group, yet adequate immunosuppression was maintained. This correlated with faster renal function recovery, with serum creatinine levels on day 4 significantly lower in the MSC group compared to controls (80 vs 101 μmol/L, p < 0.05). FISH analysis confirmed the presence of MSCs within the liver graft tissue on postoperative day 7. Conclusion. Intraportal administration of MSCs during LT is a safe approach that enhances faster graft function recovery, reduces the severity of acute rejection, and mitigates tacrolimus-associated nephrotoxicity. These findings support the potential of MSC therapy as a valuable adjunct to standard immunosuppressive regimens in LT.

  • Open Access

    Comparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow

    by E. G. Yurkina, S. I. Krivenko, В. В. Смольникова, E. A. Primakova, E. A. Nazarova, A. A. Symanovich, N. I. Dedyulya, I. A. Romanova, D. Yu. Efimov, A. E. Shcherba, et al.

    Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.

  • Open Access

    The role of soluble factors in MSC-mediated immunoregulation

    by Е. A. Prymakova, S. I. Krivenko, E. A. Nazarova, A. A. Symanovich, E. G. Yurkina, A. A. Gomon, N. I. Dedyulya, N. F. Milanovich, S. V. Korotkov

    It is known that the immunomodulatory functions of mesenchymal stem cells (MSCs) are realized through interdependent immunoregulatory network. Recently, researchers have increasingly been searching for soluble factors and molecules secreted in immunoprivileged organs and tissues and allowing to avoid the immune response. Such molecules can be galectin-1 and HLAG, which expressed on the trophoblast and ensure the development of immunotolerance.The objective of this study was a comparative analysis of the production of soluble HLA-G and galectin-1 molecules, as well as interleukin-10 by intact mesenchymal stem cells and during their co-cultivation with peripheral blood lymphocytes of recipients of allogeneic hematopoietic stem cells.As a result of the study, it was found that for the release of the soluble form of HLA-G and, consequently, the implementation of the immunomodulatory properties of MSCs, interaction between MSCs and peripheral blood lymphocytes is necessary. At the same time, the intercellular interaction of MSCs and lymphocytes did not promote increased production of galectin-1, the main contribution to the production of which in mixed cultures was made by MSCs. The level of soluble HLA-G molecule depended on the concentration of IL-10 in the culture. The revealed patterns indicate that the choice of a biomedical cell product based on MSCs should be carried out taking into account the production of soluble factors characterizing their immunoregulatory potential, which can ultimately increase the effectiveness of cell therapy.

  • Open Access

    Functional characteristics of lymphocytes and plasma cytokine profile of allogeneic hematopoietic stem cell recipients as risk factors for the development of acute graft-versus-host disease

    by E. A. Prymakova, S. I. Krivenko, A. A. Symanovich, E. G. Yurkina, E. A. Nazarova, E. A. Yanushevskaya, I. N. Dedyulya, I. A. Romanova, H. Y. Startsava, N. F. Milanovich, et al.

    It has been shown that in order to identify patients with high risk for developing immunological complications after allogeneic hematopoietic stem cell transplantation (alloHSCT), it is advisable to measure quantitatively the proliferative activity of lymphocytes in alloHSCT recipients on the day of transplantation. A high donor and recipient lymphocyte stimulation index (>11.55) is an unfavorable factor in terms of development of a graft-versus-host disease (GVHD) in the early posttransplant period. In the course of the work, it was found that the study of the cytokine profile of blood plasma of alloHSC recipients in the early posttransplant period can be used as an additional method for diagnosing GVHD. The levels of IL-8 and IL-21 in the blood plasma of alloHSC recipients can act as potential biomarkers of acute GVHD.

  • Open Access

    Usage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis

    by E. G. Yurkina, D. Yu. Efimov, S. I. Krivenko, E. A. Primakova, E. A. Nazarova, A. A. Symanovich, N. I. Dedyulya, В. В. Смольникова, E. A. Yanushevskaya, I. A. Romanova, et al.

    Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.

  • Open Access

    The use of mesenchymal stem cells in the treatment of severe forms of new coronavirus infection COVID-19: a prospective observational study

    by Aleksandr M. Dzyadzko, S. I. Krivenko, A. V. Syradouey, N. I. Dedylya, P. S. Prylutski, E. A. Prymakova, A. A. Symanovich, E. A. Nazarova, K. H. Petrovskaya, V. V. Smolnikova, et al.

    INTRODUCTION: One of the promising treatments for COVID-19 aimed at correcting the immune response and reducing the level of pro-inflammatory cytokines is the use of mesenchymal stem cells (MSCs). There is evidence that MSCs, due to various mechanisms, are able to suppress the cytokine storm in patients with COVID-19. Thus, the use of MSCs can contribute to the suppression of inflammation and the regulation of immune homeostasis in patients with severe COVID-19. OBJECTIVE: Evaluation of the effect of mesenchymal stem cell (MSC) therapy on the course of severe forms of novel coronavirus infection, accompanied by “cytokine storm”. MATERIALS AND METHODS: A prospective single-center study included 39 patients treated for coronavirus infection on the basis of the intensive care unit and, after randomization, randomly divided into control (n = 16) and study groups (n = 23). An assessment of clinical, laboratory parameters in both groups and a cytokine profile in the study group was carried out. Outcomes were compared, the incidence of complications and clinical and laboratory parameters in both groups, and the cytokine profile in the study group. RESULTS: The use of MSCs in patients with severe forms of COVID-19 affected the outcomes of the disease, the duration of stay on mechanical ventilation, the course of acute respiratory distress syndrome (ARDS) (an increase in the oxygenation index in patients of the study group by 5, 7 days from administration in comparison with the control group). CONCLUSIONS: In patients treated with MSCs, there was a significant decrease in a number of pro-inflammatory cytokines.